CMPX

Compass Therapeutics Inc

0.6846

Nov 05 • 3:59 PM ET -0.0781 (-10.24%)

0.7001

Aftermarket • 7:25 PM ET +0.0155 (2.26%)

Healthcare Biotechnology USA Micro NASD

Peers: CBIO ZYME SMMT TIL JAZZ BNTX MGNX CTMX INCY XNCR

| Held by: VTI XBI IWM VXF FESM IWN VTWO VHT IWC ITOT

Scroll to Statements

Index	RUT
Market Cap	123.29M
Enterprise Value	-46.96M
Income	-73.45M
Sales	0.00M
Book/sh	0.92
Cash/sh	1.00
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	39
IPO	Apr 05, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.74
P/C	0.69
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	11.22
Current Ratio	11.22
Debt/Eq	0.06
LT Debt/Eq	0.05
Option/Short	Yes / Yes

EPS (ttm)	-0.40
EPS next Y	-0.56
EPS next Q	-0.13
EPS this Y	-18.07%
EPS next Y	-12.68%
EPS next 5Y	-0.42%
EPS past 3/5Y	-4.18% 5.72%
Sales past 3/5Y	- -
EPS Y/Y TTM	10.44%
Sales Y/Y TTM	-100.00%
EPS Q/Q	6.33%
Sales Q/Q	-
Earnings	Aug 06 BMO
EPS/Sales Surpr.	-17.43% 100.00%

Insider Own	28.51%
Insider Trans	0.04%
Inst Own	73.23%
Inst Trans	-0.44%
ROA	-47.87%
ROE	-56.66%
ROIC	-42.20%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-15.66%
SMA50	-48.39%
SMA200	-77.84%
Trades

Shs Outstand	180.09M
Shs Float	128.74M
Short Float	32.50%
Short Ratio	9.97
Short Interest	41.84M
52W High	6.88 -90.05%
52W Low	0.73 -6.22%
Volatility	8.19% 7.25%
ATR (14)	0.07
RSI (14)	22.77
Beta	1.06
Rel Volume	0.62
Avg Volume	4.20M
Volume	2,593,136

Perf Week	-9.47%
Perf Month	-32.88%
Perf Quarter	-68.16%
Perf Half Y	-62.18%
Perf YTD	-87.25%
Perf Year	-82.08%
Perf 3Y	-63.19%
Perf 5Y	-81.19%
Perf 10Y	-
Recom	1.40
Target Price	5.50
Prev Close	0.76
Price	0.68
Change %	-10.24%

Consensus

Strong Buy

Avg. Price Target

$5.50

Implied Upside

+703.4%

Analysts16incl. previous ratings

Rating Distribution14 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 23, 2026	Downgrade	WWedbush	Outperform → Neutral	$1	+46.1%
Jul 01, 2026	Resumed	LLadenburg Thalmann	Buy	$5	+630.4%
Apr 28, 2026	Downgrade	RRaymond James	Outperform → Mkt Perform
Feb 13, 2026	Initiated	CCraig Hallum	Buy	$15	+2,091.1%
Jan 05, 2026	Initiated	WWilliam Blair	Outperform
Dec 03, 2025	Initiated	CCitizens JMP	Mkt Outperform	$10	+1,360.7%
Dec 03, 2025	Initiated	CCantor Fitzgerald	Overweight
Dec 03, 2025	Initiated	CCanaccord Genuity	Buy	$10	+1,360.7%
Jul 01, 2025	Resumed	RRaymond James	Outperform	$9	+1,214.6%
Apr 02, 2025	Upgrade	LLeerink Partners	Market Perform → Outperform	$6	+776.4%
Feb 24, 2025	Initiated	GGuggenheim	Buy	$12	+1,652.8%
Feb 19, 2025	Initiated	PPiper Sandler	Overweight	$12	+1,652.8%
Dec 23, 2024	Initiated	DD. Boral Capital	Buy	$32	+4,574.3%
Nov 15, 2024	Downgrade	LLeerink Partners	Outperform → Market Perform	$5 → $4	+484.3%
Sep 16, 2024	Upgrade	LLadenburg Thalmann	Neutral → Buy	$5	+630.4%
Jan 31, 2023	Initiated	JJefferies	Buy	$8	+1,068.6%
Jan 27, 2023	Initiated	SStifel	Buy	$9	+1,214.6%
May 23, 2022	Resumed	HH.C. Wainwright	Buy	$12	+1,652.8%
Mar 15, 2022	Initiated	LLadenburg Thalmann	Buy	$7	+922.5%
Jan 19, 2022	Initiated	RB. Riley Securities	Buy	$10	+1,360.7%

Nov-02-26 09:00AM	Compass Therapeutics to Participate in Upcoming November Investor Events (GlobeNewswire)
Oct-24-26 04:15AM	Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026 (GlobeNewswire)
Oct-16-26 11:41AM	Emergent BioSolutions stock falls as CFO plans retirement (Investing.com)
Oct-14-26 04:30PM	Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-23-26 09:49AM	Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls (The Fly) -5.65%
09:44AM	Loading…
09:44AM	Compass Therapeutics FDA Setback Raises Concerns On Wall Street H.C. Wainwright Calls Tovecimig Filing Strategy Risky (Stocktwits)
Sep-22-26 07:07PM	CMPX Plunge Wipes Out $104M After FDA Demands Fresh Trial For Cancer Drug Wedbush Sees Another 19% Downside (Stocktwits) -31.87%
10:43AM	CMPX Stock Crashes To Over 2-Year Lows Why FDA Wants Another Cancer Therapy Trial Before Key Marketing Filing (Stocktwits)
08:30AM	Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback (GlobeNewswire)
Aug-06-26 07:30AM	Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire) +5.29%
Jul-17-26 10:42AM	Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026 (GlobeNewswire)
Jun-30-26 09:00AM	A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs (PR Newswire)
May-28-26 07:30AM	Compass Therapeutics to Participate in Upcoming June Investor Events (GlobeNewswire) +6.17%
May-21-26 05:00PM	Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting (GlobeNewswire) +7.25%
May-12-26 07:30AM	Compass Therapeutics to Participate in Upcoming May Investor Events (GlobeNewswire)
07:30AM	Loading…
May-05-26 07:30AM	Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-28-26 10:30AM	BC-Most Active Stocks (Associated Press)
10:19AM	Micron initiated, Rambus downgraded: Wall Street's top analyst calls (The Fly)
07:21AM	Compass Therapeuticss stock crashes after OS miss in BTC trial (Clinical Trials Arena)
Apr-27-26 12:29PM	This Biotech Stock Is Down 61%. How a Cancer Trial Was Ruined by Its Own Design. (Barrons.com) -64.41%
10:30AM	BC-Most Active Stocks (Associated Press)
07:30AM	Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer (GlobeNewswire)
Apr-24-26 04:00PM	Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer (GlobeNewswire)
Mar-05-26 07:30AM	Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-17-26 09:40AM	Is Compass Therapeutics, Inc. (CMPX) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-29-26 09:40AM	Are Medical Stocks Lagging ResMed (RMD) This Year? (Zacks)
Jan-27-26 09:55AM	Wall Street Analysts See an 113.73% Upside in Compass Therapeutics, Inc. (CMPX): Can the Stock Really Move This High? (Zacks)
Jan-19-26 05:00PM	Compass Therapeutics, Inc. (CMPX): A Bull Case Theory (Insider Monkey)
Jan-06-26 08:00AM	Compass Therapeutics Provides Corporate Update (GlobeNewswire)
Jan-05-26 04:30PM	Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Loading…
08:00AM	Compass Therapeutics Announces Key Leadership Appointments (GlobeNewswire)
Dec-21-25 07:31AM	Compass Therapeutics' (CMPX) Tovecimig Drives Strong Analyst Sentiment (Insider Monkey)
Dec-19-25 09:40AM	Are Medical Stocks Lagging Compass Therapeutics, Inc. (CMPX) This Year? (Zacks)
Dec-17-25 07:30AM	Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference (GlobeNewswire) -5.34%
Dec-12-25 09:55AM	Wall Street Analysts Think Compass Therapeutics, Inc. (CMPX) Could Surge 134.14%: Read This Before Placing a Bet (Zacks)
Dec-08-25 12:00PM	Here's Why Compass Therapeutics, Inc. (CMPX) is a Great Momentum Stock to Buy (Zacks)
Dec-03-25 09:15AM	Here Are Wednesdays Top Wall Street Analyst Upgrades and Downgrades: American Eagle Outfitters, Equinix, Garmin, Honeywell, Uber, Wendys and More (24/7 Wall St.)
Dec-01-25 01:04AM	Strong Analyst Confidence in Compass Therapeutics (CMPX) Driven by CTX-10726 Advancement (Insider Monkey) -5.86%
Nov-26-25 09:55AM	Wall Street Analysts Believe Compass Therapeutics, Inc. (CMPX) Could Rally 154.09%: Here's is How to Trade (Zacks) +7.58%
Nov-25-25 08:00AM	Compass Therapeutics to Participate in Upcoming December Investor Events (GlobeNewswire)
Nov-24-25 05:08AM	Zacks.com featured highlights include Orla Mining, FIGS and Compass Therapeutics (Zacks)
Nov-20-25 03:00PM	2025's Top 3 Breakout Stocks for Active Traders: Don't Miss Out! (Zacks)
Nov-18-25 06:17AM	Compass Therapeutics Inc. (CMPX) is A Buy on Wall Street on Robust Pipeline Development (Insider Monkey)
Nov-05-25 07:30AM	Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-04-25 09:00AM	Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Nov-03-25 08:00AM	Compass Therapeutics to Participate in Upcoming November Investor Events (GlobeNewswire)
Oct-30-25 11:29PM	Piper Sandler Remains Bullish on Compass Therapeutics (CMPX) (Insider Monkey)
Sep-11-25 03:31AM	Guggenheim Sees Compass (CMPX) Potential Driven by Biliary Tract Cancer Pipeline (Insider Monkey)
Sep-02-25 12:57AM	Piper Sandler Reaffirms Optimism on Compass Therapeutics (CMPX) Amid Trial Update (Insider Monkey)
Aug-26-25 08:00AM	Compass Therapeutics to Participate in Upcoming September Investor Events (GlobeNewswire)
Aug-20-25 12:22AM	Compass Therapeutics (CMPX) Rated 'Outperform' amid Clinical Pipeline Development (Insider Monkey)
Aug-12-25 10:28PM	Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering (GlobeNewswire) -5.09%
04:01PM	Compass Therapeutics Announces Proposed Public Offering (GlobeNewswire)
03:03AM	Compass Therapeutics Inc (CMPX) Q2 2025 Earnings Call Highlights: Promising Clinical Advances ... (GuruFocus.com)
Aug-11-25 07:00AM	Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire) +23.70%
Aug-08-25 04:01PM	Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025 (GlobeNewswire)
Jul-25-25 12:09PM	Stifel Keeps Buy Rating on Compass Therapeutics (CMPX) (Insider Monkey)
Jul-22-25 11:03AM	Compass Therapeutics (CMPX) Gains Analyst Confidence with Promising Cancer Pipeline (Insider Monkey)
May-28-25 08:00AM	Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-08-25 08:00AM	Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
May-06-25 08:00AM	Compass Therapeutics to Participate in Upcoming May Investor Events (GlobeNewswire) -9.14%
Apr-28-25 08:00AM	Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Apr-21-25 08:00AM	Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer (GlobeNewswire)
Apr-02-25 04:05PM	Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum (GlobeNewswire) -24.55% -5.03%
Apr-01-25 07:00AM	Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer (GlobeNewswire) +17.89%
Mar-31-25 04:05PM	Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer (GlobeNewswire)
Mar-27-25 10:20AM	Is Compass Therapeutics (CMPX) The Hot Biotech Stock Under $5? (InsiderMonkey)
Mar-02-25 10:22AM	Why Compass Therapeutics, Inc. (CMPX) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-27-25 08:00AM	Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jan-29-25 08:00AM	Compass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire)
Jan-08-25 08:00AM	Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate (GlobeNewswire) +30.07%
Dec-10-24 08:00AM	Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer (GlobeNewswire) +7.88%
Dec-02-24 08:00AM	Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-13-24 08:30AM	Compass Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire) -5.59%
Nov-12-24 08:00AM	Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update (GlobeNewswire) -5.79%
Nov-08-24 10:05AM	Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Oct-04-24 10:31AM	Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Sep-03-24 08:00AM	Compass Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
Aug-12-24 08:00AM	Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-07-24 08:00AM	Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference (GlobeNewswire) -6.52%
Aug-06-24 08:00AM	Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer (GlobeNewswire)
Jul-10-24 12:00PM	Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's Why (Zacks) +9.94%
May-30-24 08:00AM	Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) -7.48%
May-28-24 04:10PM	Compass Therapeutics Announces CEO Transition (GlobeNewswire)
May-23-24 05:05PM	Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 (GlobeNewswire)
May-14-24 08:00AM	Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference (GlobeNewswire)
May-13-24 02:53PM	CMPX Stock Earnings: Compass Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-25-24 08:00AM	Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated (GlobeNewswire)
Apr-16-24 08:00AM	Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors (GlobeNewswire)
Apr-12-24 08:00AM	Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference (GlobeNewswire)
Apr-10-24 08:00AM	Compass Therapeutics to Participate in the Stifel Targeted Oncology Days (GlobeNewswire)
Apr-09-24 12:00PM	Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-21-24 10:54PM	CMPX Stock Earnings: Compass Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +5.66%
09:00AM	Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-29-24 08:00AM	Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-28-24 08:00AM	Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial (GlobeNewswire)
Feb-08-24 12:00PM	Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's What You Should Know (Zacks) +8.21%
Jan-05-24 08:00AM	Compass Therapeutics Provides Corporate Update (GlobeNewswire) +5.16%
Nov-09-23 08:17AM	Compass Therapeutics Inc (CMPX) Reports Q3 2023 Financial Results and Corporate Developments (GuruFocus.com) -6.40%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lerner Neil	Chief Accounting Officer	Oct 01 '26	Buy	0.92	20,000	18,400	420,000	Oct 02 08:00 AM
Lerner Neil	Chief Accounting Officer	Sep 24 '26	Buy	1.14	2,500	2,850	400,000	Sep 25 08:01 AM

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

Ph.D.Dr. Thomas J. Schuetz M.D.

M.B.A.Mr. Barry Shin J.D.

Senior VPMr. Jonathan E. Anderman J.D.

Senior VP & Chief Accounting OfficerMr. Neil L. Lerner CPA

Chief Scientific OfficerMr. Bing Gong Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CMPX

Compass Therapeutics Inc

Upgrade your Finviz experience